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Abstract
Glycosuria is a condition where glucose is detected in urine at higher concentrations than normal (i.e. not detectable).
Glycosuria at some point during pregnancy has an estimated prevalence of 50% and is associated with adverse outcomes in
both mothers and offspring. Little is currently known about the genetic contribution to this trait or the extent to which it
overlaps with other seemingly related traits, e.g. diabetes. We performed a genome-wide association study (GWAS) for
self-reported glycosuria in pregnant mothers from the Avon Longitudinal Study of Parents and Children
(cases/controls = 1249/5140). We identified two loci, one of which (lead SNP = rs13337037; chromosome 16; odds ratio of
glycosuria per effect allele: 1.42; 95% CI: 1.30, 1.56; P = 1.97 × 10−13) was then validated using an obstetric measure of
glycosuria measured in the same cohort (227/6639). We performed a secondary GWAS in the 1986 Northern Finland Birth
Cohort (NFBC1986; 747/2991) using midwife-reported glycosuria and offspring genotype as a proxy for maternal genotype.
The combined results revealed evidence for a consistent effect on glycosuria at the chromosome 16 locus. In follow-up
analyses, we saw little evidence of shared genetic underpinnings with the exception of urinary albumin-to-creatinine ratio
(Rg = 0.64; SE = 0.22; P = 0.0042), a biomarker of kidney disease. In conclusion, we identified a genetic association with
self-reported glycosuria during pregnancy, with the lead SNP located 15kB upstream of SLC5A2, a target of antidiabetic
drugs. The lack of strong genetic correlation with seemingly related traits such as type 2 diabetes suggests different genetic
risk factors exist for glycosuria during pregnancy.
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Introduction
At normal levels, glucose is not detectable in urine. Glycosuria,
the presence of glucose in urine above normal levels, may be
caused by either an increase in blood glucose such that the renal
tubules are overwhelmed and complete reabsorption of pre-
sented glucose is not possible, a lowering of the renal threshold,
or inhibition of renal tubule reabsorption (1). Although preva-
lence estimates for glycosuria vary, it seems likely that the
condition effects around 50% of women at some stage of their
pregnancy (2) and is thought to occur primarily as a result of
pregnancy-related increases in renal blood flow resulting in a
lower threshold for excreting glucose in urine. It also reflects
pregnancy-related increases in circulating blood glucose. While,
outside of pregnancy, glycosuria is considered a diabetes indi-
cator, glycosuria in pregnancy is not specific or sensitive for
gestational diabetes risk and is not recommended as a screening
tool for it (2,3).
There is evidence that glycosuria is associated with adverse
cardio-metabolic outcomes, including non-alcoholic fatty liver
disease, in offspring (4–6) and with later life outcomes, such
as cardiovascular disease death, in mothers (7). Therefore, the
presence of glycosuria may potentially indicate future adverse
outcomes in pregnancy and the life course.
Both glucose regulation and renal function are heritable, with
reliable evidence for several genetic variants being associated
with a range of relevant traits, including fasting glucose (8,9),
insulin sensitivity (8,9), type 2 diabetes (10) and glomerular
filtration rate in general non-pregnant populations (11). While
these studies have yielded valuable new insights into glucose
metabolism, still outstanding is an investigation of the genetic
contribution to glycosuria during pregnancy. To investigate
whether common genetic variants are associated with glucose
in urine during pregnancy and to explore potential links to
other glycaemic and renal-function-related traits, we set out to
conduct a genome-wide association study (GWAS) of glycosuria
during pregnancy in the Avon Longitudinal Study of Parents
and Children (ALSPAC) and looked for confirmatory evidence in
the Northern Finland Birth Cohort 1986 (NFBC1986). We further
investigated the genetic overlap between identified loci and
multiple diabetes-related traits.
Results
A genome-wide association study (GWAS) of self-reported gly-
cosuria during pregnancy performed in ALSPAC represents our
primary analysis. Additional work exploring associations further
was conducted in the same cohort. Due to lack of available data,
a replication GWAS was not possible. We instead sought sup-
porting evidence from a secondary GWAS analysis performed
in NFBC1986 and combined GWAS results from ALSPAC and
NFBC1986 to identify persistent associations. An overview of the
study and its components is presented in Figure 1 and Supple-
mentary Material, Figure S1.
Primary Analysis
ALSPAC GWAS
Assuming an additive genetic model, the estimated variance
explained by genotype across all variants in ALSPAC was
estimated to be 1.6% (standard error (SE) = 0.08), corresponding
to an estimated narrow-sense heritability of 10% (SE = 0.05,
12–14). There was evidence for association at genome-wide
significance (P-value = 5 × 10−8) at 55 SNPs (Supplementary
Material, Figures S2, S3 and Supplementary Material, Table S1)
across chromosomes 16 (Fig. 2) and 9 (Supplementary Material,
Figure S4). The lead SNP on chromosome 16 was rs13337037
(odds ratio (OR) of glycosuria per A allele: 1.42; 95% confidence
interval (CI): 1.30, 1.56; P-value = 1.97 × 10−13; minor allele
frequency (MAF) = 28%; Fig. 2) and the only SNP on chromosome
9 was rs10991823 (OR of glycosuria per T allele: 1.47; 95% CI: 1.29,
1.68; P-value = 4.02 × 10−8; MAF = 10%; Supplementary Material,
Figure S4). The lead SNP on chromosome 16 is part of a block of
17 SNPs in high linkage disequilibrium (LD; R2 > 0.8; Fig. 2) in a
region containing multiple genes: ARMC5, TGFB1I1, SLC5A2 and
C16orf58. The lead SNP on chromosome 9 is part of a block of
25 SNPs in high LD (R2 > 0.8; Supplementary Material, Figure S4)
surrounding the AUH gene. Conditional analysis did not reveal
any additional associations on either chromosome.
The correlation between self-reported glycosuria and glyco-
suria determined by reagent strip was 0.31 (P-value = 2.2 × 10−16;
Supplementary Material, Table S2). Logistic regression showed
the association of rs13337037 with glycosuria was stronger (with
overlapping confidence intervals) when glycosuria was deter-
mined by reagent strip (OR per A allele of a positive reagent
strip test result: 1.64; 95% CI: 1.35, 2.00; P-value = 6.72 × 10−7).
The corresponding OR for rs10991823 was 1.10 (OR per T allele
of a positive reagent strip test result: 1.10; 95% CI: 0.82, 1.48;
P-value = 0.51).
Secondary analysis
In a GWAS performed in NFBC1986 using offspring genotype and
maternal midwife-reported glycosuria, there was evidence for
an association (P-value = 5 × 10−8) at 49 SNPs on chromosome
6 (Supplementary Material, Figures S5, S6 and Supplementary
Material, Table S3). To evaluate the persistence of signal across
the two cohorts, association results were combined. This
revealed evidence for a consistent effect on glycosuria at
rs13337037 on chromosome 16 only (Z-score: 7.833; P-value: 4.75
× 10−15; effect allele = A; MAF = 27%) (Supplementary Material,
Figures S7, S8 and Supplementary Material, Table S4). The effect
estimate for rs13337037 in NFBC1986 was OR: 1.25 (5% CI: 1.12,
1.38; P-value = 9.8 × 10−4; effect allele = A; MAF = 26%). The re-
scaling of this effect size to approximate the allelic effect in
mothers (15,16), as in ALSPAC, gave an OR of 1.57 (95% CI, 1.30,
1.83). Results of analyses undertaken to test the validity of this
re-scaling are presented in Supplementary Information and
Supplementary Material, Table S5.
Additional analysis
Overlap of genome-wide significant SNPs in ALSPAC with other
GWASs. None of the SNPs reaching genome-wide significance
(P-value = 5 × 10−8) in the primary analysis showed evidence of
association with fasting insulin (8), fasting glucose (8), HbA1c (9),
type 2 diabetes (10), BMI (17) or estimated glomerular filtration
rate (11) at a genome-wide level of significance (Supplementary
Material, Table S5). In a comparison of effect estimates of SNPs
associated with each of these traits and the estimates for the
same SNPs in our GWAS of glycosuria, the strongest correlation
was found with estimated glomerular filtration rate (r2 = −0.44;
95% CI = −0.54, −0.34; P-value = 5.78 × 10−13), with weaker cor-
relations found for type 2 diabetes (r2 = 0.08; 95% CI = 0.04, 0.13;
P-value = 0.0005) and HbA1c (r2 = −0.07; 95% CI = −0.14, −0.001;
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Figure 1. Analysis overview. The flowchart provides an overview of GWAS follow-up analysis.
Figure 2. Regional association plot of lead association on chromosome 16 (rs13337037) in ALSPAC GWAS. P-values (on a −log10 scale) in ALSPAC are shown. Each SNP is
coloured according to the degree of LD with the lead SNP rs13337037 (shown as a purple diamond). LD values are from the 1000 Genomes (March 2012 release) European
population (created using locuszoom.org build: hg19).
Linkage disequilibrium score regression. Of the 832 traits avail-
able in LD Hub (date accessed: 19/02/2019), genetic correlations
were not returned for 81 traits, with a further two traits showing
correlations above 1 and below −1 (LDSR mean Chi2 = 1.022).
Our main focus was on trait categories from LD Hub that were
a priori related to glycosuria (anthropometric, cardiometabolic,
glycaemic, kidney, reproductive), and results for these are shown
in Supplementary Material, Table S6. Of the 43 traits from
the categories of interest, those that showed the strongest
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albumin-to-creatinine ratio in non-diabetes (Rg = 0.7; SE = 0.24; P-
value = 0.004) and urinary albumin-to-creatinine ratio (Rg = 0.64;
SE = 0.22; P-value = 0.004).
Functional informatics. We passed the rs13337037-defined
signal (including SNPs in high LD) through the Ensembl Variant
Effect Predictor. All SNPs were existing variants with the
‘MODIFIER’ impact annotation, suggesting they are non-coding
variants or variants affecting non-coding genes (Supplemen-
tary Material, Table S7). rs13337037 is a non-coding variant
downstream of ARMC5 (a member of the ARM (armadillo/beta-
catenin-like repeat) superfamily implicated in mediation of
protein–protein interactions (18)) and upstream of TGFB1I1
(coactivator of the androgen receptor (19)) and SLC5A2; there
was a weak evidence of an impact on any of these genes from
the lead SNP (Supplementary Material, Table S7).
In GTEx, there was evidence that rs13337037 acts as a cis-
eQTL (expression quantitative trait locus) for a number of nearby
genes, including ARMC5, TGFB1I1, SLC5A2 and ZNF843 across a
number of different tissues (Supplementary Material, Table S8).
Discussion
In a GWAS analysis of glycosuria during pregnancy conducted
in ALSPAC (a European longitudinal cohort), we identified an
association between a block of common SNPs with high LD sur-
rounding multiple genes (ARMC5, TGFB1I1, SLC5A2 and C16orf58)
on chromosome 16 and self-reported phenotype. When exam-
ining the relationship between rs13337037 and glycosuria deter-
mined by reagent strip, we found consistent evidence for asso-
ciation despite differences in sample size and the frequency of
glycosuria status. Each A allele of rs13337037 was associated
with a 47% increased risk of self-reported glycosuria and a
64% increased risk of glycosuria determined by reagent strip.
While we lacked fully replicable datasets for our GWAS of self-
reported glycosuria, we instead made use of offspring genotype
as a predictor for maternal genotype in the NFBC1986 collection.
The only signal that persisted in efforts to filter out chance
associations in ALSPAC by combining GWAS results from the two
cohorts was that at rs13337037 on chromosome 16.
rs13337037 lies 15 kb upstream of SLC5A2 and, while it is
difficult to assert a direct relationship between neighbouring
loci and signal at specific SNPs (20), evidence has implicated
SLC5A2 in familial renal glycosuria (21,22). SLC5A2 encodes a
low-affinity, high-capacity Na(+)/glucose cotransporter (SGLT2,
sodium glucose cotransporter 2) (23). For the other genes sur-
rounding the lead SNP on chromosome 16, their relation to
glycosuria is unclear: ARMC5 is implicated in mediation of pro-
tein–protein interactions (18) and may act as a tumour sup-
pressor (24) (date accessed: 02/22/2019—https://www.ncbi.nlm.
nih.gov/gene/79798); TGFB1I1 encodes a protein that acts as a
coactivator of the androgen receptor (19) and which may be
involved in prostate cancer (25) (date accessed: 02/22/2019—
https://www.ncbi.nlm.nih.gov/gene/7041); C16orf58 is not well
characterized but is thought to be involved in protein–protein
interaction (date accessed: 02/22/2019—https://www.ncbi.nlm.
nih.gov/gene/64755).
Sodium glucose cotransporters mediate the reabsorption of
glucose in the kidney, with the SLC5A2-encoded SGLT2 responsi-
ble for 90% of this glucose reabsorption and SGLT1 (high affinity
and low capacity) responsible for the remaining ∼ 10% (23). Stud-
ies show SGLT2 levels are increased in diabetic patients com-
pared with non-diabetics, though the mechanism for this is not
understood (1). In adults with type 2 diabetes, pharmaceutical
targeting of renal glucose reabsorption by inhibition of SGLT2
can be successful at improving glycaemic control via excretion of
glucose in urine (26). These gliflozin inhibitors act independently
of insulin, providing a novel therapeutic avenue (26). Aberrant
expression of SGLT2 is known to result in glycosuria (23), though,
due to mutations within the SLC5A2 locus mostly being within
families, common mutations have yet to be identified. In GTEx,
there is evidence that rs13337037 acts as a cis-eQTL for SLC5A2.
In a clinical setting, the relationship between glycosuria
during pregnancy and other related metabolic traits such
as fasting blood glucose and type 2 diabetes (either during
pregnancy or more generally) is unclear. In our exploration of
the shared genetic contribution to glycosuria during pregnancy
and other metabolic traits, we found that while there was
no overlap in genome-wide significant hits across the traits,
estimates of shared heritable contribution (i.e. considering
genetic effects across the entire genome) identified urinary
albumin-to-creatinine ratio as the most strongly correlated
trait. While the LDSR approach used for these analyses provides
only an approximation of genetic correlation and results should
ideally be followed up by more detailed analyses (27), these
preliminary findings suggest that renal function may be an
important component of glycosuria.
Limitations
We used a glycosuria measurement that was retrospectively
reported by mothers in pregnancy for our main ALSPAC analyses.
This is likely to be reported with error and will likely include
women with very different levels of glycosuria (for example, it
may include women who were told they had ‘a trace of sugar’ in
their urine as well as those with higher levels). This is supported
by the higher prevalence of glycosuria defined by retrospective
report compared with the definition used for glycosuria deter-
mined by reagent strip of at least ‘++’ on at least two occasions
from all glycosuria measures in antenatal records (20% versus
4%). However, these two measures were correlated. Any mis-
classification of this maternal retrospective report is likely to be
non-differential by genotype (as the women will not know their
genotype) and so would be expected to attenuate any genome-
wide results towards the null. This is consistent with our finding
that the lead SNP was more strongly associated with the reagent
strip measure of glycosuria than with the retrospective report.
In the absence of other studies with both glycosuria assessed
during pregnancy and corresponding associated genome-wide
genetic data, we were limited in our ability to perform an inde-
pendent replication of the GWAS performed in ALSPAC. However,
we were able to look for persistent signal using results from
a GWAS performed in NFBC1986 using offspring genotype. It
has been suggested that allelic effect estimates derived in this
way can be re-scaled (multiplied by 2) to give an approxima-
tion of the allele effect in the mother. However, given that
this re-scaling is based on expectation, one can expect the
actual multiplication factor, in any given instance, to vary around
this expectation. Furthermore, we did not carry out a com-
prehensive validation of this approach within the context of
this study, where additional issues such as the potential for
a direct effect of offspring genotype on maternal glycosuria
phenotype could be relevant. Therefore, while the combined
results indicate persistence of the primary signal across the two
datasets and we see reasonable agreement with respect to the
magnitude of effect in the two studies, our results should be
treated with caution until replicated, preferably in independent
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Summary
Our GWAS of reported glycosuria during the third trimester of
pregnancy has identified associations of genetic variants on
chromosome 16 near multiple genes, including SLC5A2, which
has been implicated in familial renal glycosuria and the gene
product of which is the target of some type 2 diabetes drugs
(gliflozins, e.g. Dapagliflozin). Furthermore, hypothesis-free
genetic correlation analysis suggested genetic loci underpinning
glycosuria susceptibility may be linked with kidney disease,
reflecting the joint role of circulating glucose and renal function
on glycosuria and the possible effect of hyperglycaemia on
renal function. This shared heritability suggests distinguishing
gestational diabetes from other presentations of diabetes or




Participants were mothers from ALSPAC, a large prospective
cohort study that recruited 14 541 pregnancies in the former
Avon Health Authority area in South West England, with
expected delivery dates between the 1st April 1991 and the
31st December 1992 (28,29) (see Supplementary Information,
ALSPAC Overview, for full details). The study website (http://
www.bristol.ac.uk/alspac/) contains details of all the data that is
available through a fully searchable data dictionary and variable
search tool (http://www.bristol.ac.uk/alspac/researchers/our-
data/). Ethical approval for the study was obtained from the
ALSPAC Ethics and Law Committee and the Local Research Ethics
Committees (http://www.bristol.ac.uk/alspac/researchers/resea
rch-ethics/). Informed consent for the use of data collected
via questionnaire and clinics was obtained from participants
following recommendations of the ALSPAC Ethics and Law
Committee at the time. Full details of the ALSPAC consent
procedures are available on the study website (http://www.bri
stol.ac.uk/alspac/researchers/research-ethics/).
ALSPAC phenotype data
Self-reported glycosuria. We used two measures of glycosuria
in ALSPAC (Supplementary Material, Figure S1). Firstly, moth-
ers were sent a pregnancy-related self-report questionnaire
approximately 8 weeks after the end of their pregnancy, which
included the following question: ‘During the last months of
pregnancy (from seven months onwards) did you experience
sugar in urine?’, with possible answers ‘yes, in the last months of
pregnancy’, ‘no, not in the last months of pregnancy’ and ‘don’t
know’. In total, 11 710 women returned the questionnaire and
11 660 (99%) answered this question, with 2389 (21%) responding
‘yes, in the last months of pregnancy’. Of the 11 660 women who
answered the glycosuria question, 7429 (64%) had genetic data
and, of these, 1519 (20%) self-reported having glycosuria.
At recruitment, women were also asked about existing dia-
betes and any previous history of gestational diabetes. Women
were classified into one of four mutually exclusive categories:
no evidence of glycosuria or diabetes (n = 11 773), existing dia-
betes before the pregnancy (n = 47), gestational diabetes (i.e. a
diagnosis written in the medical records of gestational dia-
betes in any woman with no history of existing diabetes; n = 57)
and glycosuria (i.e. ++ glycosuria on two occasions in women
with no evidence of existing or gestational diabetes; n = 404)
(4,5). Of the 7429 women with phenotype and genetic data, we
excluded those without information on pre-existing diabetes
and gestational diabetes and glycosuria, and those with pre-
existing diabetes or gestational diabetes, leaving 7089 (61% of
11 660 respondents), of whom, 1399 (20%) self-reported having
glycosuria. After excluding women who had withdrawn consent
for the phenotype and genetic data, and related individuals, 6639
(93%) women had self-reported glycosuria data and genotype
data. Finally, we removed women who did not have information
on our second measure of glycosuria (glycosuria determined by
reagent strip), leaving 6389 (96%; 55% of 11 660) women of whom
1249 (20%) self-reported having glycosuria.
Reagent strip defined glycosuria. Due to potential misreporting
in the postnatal questionnaire response, we also generated a
variable based on objectively measured reagent strip tests of
pregnancy glycosuria (glycosuria determined by reagent strip).
Information on glycosuria (recorded in the obstetric records as
none, trace, +, ++, +++ or more) was abstracted from the records
of each antenatal clinic visit made by the woman (median num-
ber, 12 per woman (interquartile range: 9–14)). Glycosuria was
defined as a record of at least ++ (equal to 13.9 mmol/l or
250 mg/100 mL) on at least two occasions at any time during the
pregnancy. In total, 12 281 women had information on reagent
strip defined glycosuria.
Of the 12 281 women with information on reagent-strip-
determined glycosuria, we excluded those without information
on pre-existing diabetes and gestational diabetes and glycosuria,
and those with pre-existing diabetes or gestational diabetes.
Of the remaining 12 177 women, 404 (3%) fulfilled our criteria
for glycosuria and 7652 (63%) had available genetic data. Of
the 7652 women, 261 (3%) fulfilled our criteria for glycosuria.
After excluding women withdrawing consent for the phenotype
and genetic data, as well as related individuals, 6866 (91%)
women had data on glycosuria determined by reagent strip
and genotype data, of which 227 (3%) fulfilled our criteria for
glycosuria.
ALSPAC genotype data
Imputation of ALSPAC mother’s genetic data was performed on
a combined mother and child data set using Impute2 against
the 1000 Genomes Phase 1 reference panel (30). ALSPAC mothers
were genotyped using the Illumina human660W-quad array at
Centre National de Génotypage (CNG). For ALSPAC mothers,
SNPs with a minor allele frequency (MAF) of <1%, a call rate
of <95%, or evidence for violations of Hardy–Weinberg equi-
librium (P < 1 × 10−06) were removed. ALSPAC children were
genotyped using the Illumina HumanHap550 quad chip geno-
typing platforms by 23andMe subcontracting the Wellcome Trust
Sanger Institute, Cambridge, UK and the Laboratory Corporation
of America, Burlington, NC, USA. For ALSPAC children, SNPs with
MAF of <1%, a call rate of <95% or evidence for violations of
Hardy–Weinberg equilibrium (P < 5 × 10−7), were removed. In
total, we removed 1946 individuals based on relatedness and
withdrawal of consent for both genotype and the phenotype
data, leaving 15 896 individuals for further analysis, of which
7921 were mothers. See Supplementary Information for full
details on ALSPAC genetic data and imputation.
NFBC1986 overview
The Northern Finland Birth Cohort 1986 (NFBC1986) is a prospec-
tive birth cohort that recruited women in the two northern-
most provinces of Finland (Oulu and Lapland) with an expected
delivery date between 1st July 1985 and 30th June 1986. A total
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of all eligible births in the region being recruited (n = 9432 live
born children) (31)(Supplementary Material, Figure S1). Informed
written consent was obtained from all participants, and the
research protocols were approved by the Ethics Committee of
Northern OStrobothnia Hospital District, Finland.
NFBC1986 phenotype data
Data were gathered prospectively at the first antenatal clinic
visit and onwards (mean gestational age at inclusion = 12 weeks).
Mothers provided information on maternal background via
self-report questionnaires. Data on antenatal visits, hospital
admissions and birth outcomes were obtained from maternity
health centres and hospital medical records. Midwives were
given questionnaires to complete during the mother’s last visit
to the antenatal care unit or during the first home visit after
the delivery, which included the following question: ‘urinary
glucose’ with possible answers ‘+’ (equivalent to yes) and ‘−’
(equivalent to no) (31). Pregnancy questionnaires are available
at the NFBC1986 pregnancy and antenatal data website (https://
www.oulu.fi/nfbc/node/18143), with information on glycosuria
reported in ‘Pregnancy Questionnaire II (yellow form)’, question
7.
Of the 9362 women included in the study, 9336 had data
available on midwife-reported glycosuria. Of these 9336, 1789
(19%) were reported with ‘+’. Of the 9336 women with available
midwife-reported glycosuria, 3738 (40%) had quality-controlled
offspring genetic data available and, of these mothers, 747 (20%)
were reported as having glycosuria.
For this GWAS, maternal genotype data were not available
and so we tested for an association of offspring genotype with
midwife-reported glycosuria as our main outcome.
NFBC1986 genotype data
In the absence of genetic data for the mothers in NFBC1986,
we used offspring genome-wide data, as a proxy for mater-
nal genotype in this cohort. NFBC1986 children were invited to
clinic at age 16 and 3834 individuals with consent were geno-
typed using the Illumina OmniExpressExome-8v1.2 Chip and the
GenomeStudio algorithm. Quality control comprised of exclu-
sions based on sex mismatch, outlying heterozygosity, duplicate
samples and relatedness, after which genotype data were avail-
able for 3743 individuals—five of which had no information on
mother’s glycosuria during pregnancy. After excluding SNPs not
in Hardy–Weinberg equilibrium (P < 0.0001) or with low call rate
(<0.99), imputation was performed using Impute2 against the
1000 Genomes Phase 3 reference panel (30). The total number of
individuals with genotype and phenotype information was 3738
and of these 747 (20%) had glycosuria.
Primary analysis
ALSPAC GWAS. The total number of variants after imputation
equalled 28 699 509. Prior to genome-wide analysis, SNPs were
filtered based on an info score threshold of ≥0.3 and a MAF
threshold of ≥0.01, leaving 9 323 831 variants in the analysis.
Testing an additive genetic model, we carried out a GWAS of
imputed data on self-reported glycosuria in the third trimester
of pregnancy (1249 cases and 5140 controls) using logistic regres-
sion and adjusting for the top 10 principal components of genetic
ancestry to control for potential confounding by population
stratification in SNPTEST (v2.5.2). We present all GWAS results
and focus on those that satisfy a conventional genome-wide
significance threshold of P-value ≤5 × 10−8. Full details of how
the GWAS was performed, including how principal components
were generated, are provided in the Supplementary Information.
We estimated the proportion of variance explained by all SNPs
in our GWAS using GCTA (v1.26.0) (12–14). We carried out condi-
tional analysis with the lead SNPs coded as an additive effect for
evidence of secondary signals on the same chromosome using
SNPTEST (v2.5.2) and appraised the pattern of association at our
lead SNPs using LocusZoom (32).
Within-cohort validation. We examined the relationship between
self-reported glycosuria and glycosuria determined by reagent
strip performing a Pearson’s correlation test in R (33) (version
R-3.5). We investigated the relationship between glycosuria
determined by reagent strip and the lead SNPs, assessing the
odds per effect allele of a positive response for reagent strip
glycosuria using logistic regression in R.
Secondary analysis
NFBC1986 GWAS. The total number of variants after impu-
tation equalled 81 571 831. We performed a logistic regression
GWAS using SNPTEST (version 2.5) with the mother’s glycosuria
in pregnancy as the outcome and offspring’s imputed genotype
as the predictor of interest, assuming an additive model and
including the top four multidimensional scaling (MDS) coordi-
nates as covariates to adjust for population stratification (34).
We filtered results based on an info score threshold of ≥0.3
and an MAF threshold of ≥0.01, resulting in 9 873 828 variants.
We present all GWAS results and focus on those that satisfy a
conventional genome-wide significance threshold of P-value ≤5
× 10−8.
Based on quantitative genetics theory (i.e. the rules of inher-
itance) and assuming an additive genetic effect, we expected
that any allelic effect estimated in the NFBC1986 analysis (i.e.
using offspring genotype in place of mother’s own) would be
smaller compared to that observed using own genotype. More
specifically, it has previously been suggested that the average
(expected) allelic effect of one allele in the offspring (on the
parental phenotype) is half the effect that would be observed
using the parent’s own genotype (15,16). Further consideration
of the validity of this re-scaling approach in the context of this
study is presented in the Supplementary Information.
Combined analysis. In order to evaluate the persistence of signal
across the two cohorts, association results from the two cohorts
were combined. Given the different designs of the two analyses
(i.e. the substitution of offspring genotype for mother’s genotype
in the NFBC1986 GWAS), we performed a sample size-based
approach in which the direction of effect and P-value observed
in each study are converted into a signed Z-score indicating
the strength and direction of effect (35). Z-scores for each allele
were then combined across studies in a weighted sum, with
weights proportional to the square root of the effective sample
size for each study. We present all combined results and consider
any associations reaching a conventional genome-wide signifi-
cance threshold of P-value ≤5 × 10−8 as providing evidence of a
persistent signal.
Additional analysis
Overlap of genome-wide significant SNPs in ALSPAC with other
GWASs. To investigate evidence of overlap of association
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traits, we examined whether SNPs associated with glycosuria in
pregnancy in ALSPAC are also associated with the following
traits at a genome-wide significance threshold of P-value
≤5 × 10−8: HBA1c (9), fasting insulin (8), fasting glucose (8),
type 2 diabetes (10), BMI (17), estimated glomerular filtration
rate (11) (see Supplementary Information for full details of
summary level data used). In addition, we explored concordance
between effect estimates for SNPs reaching genome-wide
significance (P-value ≤5 × 10−8) extracted from GWAS for the
aforementioned traits and effect estimates for the same SNPs
in our GWAS of glycosuria. Data were visualized in scatter
plots and concordance assessed via Pearson’s product-moment
correlation. The numbers of SNPs included in this analysis were
as follows: type 2 diabetes = 1792, estimated glomerular filtration
rate = 4196, BMI = 1860, fasting glucose = 290 and HBA1c = 821.
Linkage disequilibrium score regression. Using results from the
ALSPAC GWAS, we estimated the genetic correlation of glyco-
suria with the 832 available traits in LD Hub (http://ldsc.broa
dinstitute.org/ldhub/) using linkage disequilibrium (LD) score
regression (LDSR) (36).
Functional informatics. To identify potential functional roles of
lead SNPs, we examined the effects of lead SNPs and SNPs in high
LD (R2 ≥ 0.8) on genes and regulatory regions via the Ensembl
Variant Effect Predictor (37). We examined the effect of lead SNPs
in GTEx (20).
Supplementary material
Supplementary Material is available at HMG online
Data and Material Availability
Data are available from the Northern Finland Birth Cohort (NFBC)
for researchers who meet the criteria for accessing confidential
data. Please contact NFBC project centre (NFBCprojectcenter@ou
lu.fi) and visit the cohort website (www.oulu.fi/nfbc) for more
information.
Code for the analysis and visualization of the data is available
at: https://github.com/mattlee821/001_glycosuria_GWAS
Summary statistics from GWAS are available at data.bris—
https://doi.org/10.5523/bris.9vjsikubd658257lbu6lrizog
ALSPAC data used for this submission will be made available
on request to the ALSPAC Executive via the website, which
also provides full details and distributions of the ALSPAC
study variables: http://www.bristol.ac.uk/alspac/researchers/a
ccess/. The ALSPAC data management plan (available here:
http://www.bristol.ac.uk/alspac/researchers/data-access/docu
ments/alspac-data-management-plan.pdf) describes in detail
the policy regarding data sharing. A sample set of similar
data containing relevant ALSPAC variables is available from
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